BR0318659A - derivados de prolina usados como ingredientes farmacêuticos ativos no tratamento de tumores - Google Patents

derivados de prolina usados como ingredientes farmacêuticos ativos no tratamento de tumores

Info

Publication number
BR0318659A
BR0318659A BRPI0318659-8A BR0318659A BR0318659A BR 0318659 A BR0318659 A BR 0318659A BR 0318659 A BR0318659 A BR 0318659A BR 0318659 A BR0318659 A BR 0318659A
Authority
BR
Brazil
Prior art keywords
treatment
tumors
proline derivatives
active pharmaceutical
pharmaceutical ingredients
Prior art date
Application number
BRPI0318659-8A
Other languages
English (en)
Inventor
Sven Lange
Original Assignee
Zoser B Salama
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zoser B Salama filed Critical Zoser B Salama
Publication of BR0318659A publication Critical patent/BR0318659A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"DERIVADOS DE PROLINA USADOS COMO INGREDIENTES FARMACêUTICOS ATIVOS NO TRATAMENTO DE TUMORES". A invenção refere-se aos derivados de prolina e seus sais, aos agentes farmacêuticos que contêm seus sais e o uso dos mencionados agentes para o tratamento de tumores. Além disso, a invenção também se refere à fabricação dos compostos acima mencionados e seus agentes farmacêuticos.
BRPI0318659-8A 2003-12-18 2003-12-18 derivados de prolina usados como ingredientes farmacêuticos ativos no tratamento de tumores BR0318659A (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/DE2003/004211 WO2005058816A1 (de) 2003-12-18 2003-12-18 Prolinderivate als pharmazeutische wirkstoffe in der tumortherapie

Publications (1)

Publication Number Publication Date
BR0318659A true BR0318659A (pt) 2006-11-28

Family

ID=34683207

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0318659-8A BR0318659A (pt) 2003-12-18 2003-12-18 derivados de prolina usados como ingredientes farmacêuticos ativos no tratamento de tumores

Country Status (10)

Country Link
US (1) US20080176923A1 (pt)
EP (1) EP1711462A1 (pt)
JP (1) JP2007523829A (pt)
CN (1) CN1942438A (pt)
AU (1) AU2003298077A1 (pt)
BR (1) BR0318659A (pt)
CA (1) CA2548391A1 (pt)
MX (1) MXPA06007007A (pt)
UA (1) UA82753C2 (pt)
WO (1) WO2005058816A1 (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2007101074A (ru) 2004-06-14 2008-07-20 Зозер Б. САЛАМА (DE) Фармацевтическая противораковая композиция пролина или его производных и противоопухолевого антитела
CN100396666C (zh) * 2005-12-14 2008-06-25 郑州大学 （4s）-1-叔丁氧羰基-4-氨基-l-脯氨酸乙酯及其合成工艺
AU2011292044A1 (en) * 2010-08-18 2013-04-04 Del Mar Pharmaceuticals Compositions and methods to improve the therapeutic benefit of suboptimally administered chemical compounds including substituted hexitols such as dianhydrogalactitol and diacetyldianhydrogalactitol
EP2804602B1 (en) * 2012-01-20 2024-12-04 Del Mar Pharmaceuticals Use of substituted hexitols including dianhydrogalactitol and analogs to treat neoplastic disease and cancer stem cells including glioblastoma multforme and medulloblastoma
WO2013169600A1 (en) 2012-05-09 2013-11-14 Delmar Pharmaceuticals Veterinary use of dianhydrogalactitol, diacetyldianhydrogalactitol, and dibromodulcitol to treat malignancies
IL283717B (en) 2013-03-15 2022-09-01 Cancer Research Tech Llc Methods and compositions for gamma-glutamyl cycle modulation
WO2016046162A1 (en) * 2014-09-22 2016-03-31 Salama Zoser B Proline or proline derivatives for the treatment of dementia
CN105061282A (zh) * 2015-07-28 2015-11-18 黑龙江省科学院石油化学研究院 氢解合成α,α-二苯基-2-吡咯烷甲醇的方法
WO2021054448A1 (ja) * 2019-09-20 2021-03-25 美智子 甲賀 ペプチド並びにそれを含む細胞融合剤及びがん治療用医薬組成物
CN113968808B (zh) * 2021-11-26 2024-04-09 河南中医药大学 一类水苏碱衍生物的制备方法及其应用
CN114028388B (zh) * 2021-12-16 2023-05-12 郑州大学第一附属医院 脯氨酸在制备肺癌治疗药物中的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4499287A (en) * 1981-02-02 1985-02-12 E. R. Squibb & Sons, Inc. Certain-4-hydroxy-proline derivatives
CA1281288C (en) * 1984-11-05 1991-03-12 Wilhelm Hoerrmann Tumor therapy
DE3518078A1 (de) * 1985-05-20 1986-11-20 Wilhelm Dr. 8127 Iffeldorf Hoerrmann Arzneimittel, die derivate des prolin oder hydroxyprolin enthalten
JPH05213957A (ja) * 1992-02-07 1993-08-24 Tsumura & Co 新規なスピロピロリジンイミダゾリン誘導体および新規なアミノピロリジンカルボン酸誘導体並びに該化合物を有効成分とする鎮けい剤
CA2248765A1 (en) * 1996-03-11 1997-09-18 Wilhelm Hoerrmann Combination of cis-4-hydroxy-l-proline and n-methyl-cis-4-hydroxy-l-proline for use as a therapeutic agent, in particular in cancer treatment
WO2002053555A2 (en) * 2001-01-05 2002-07-11 Eli Lilly And Company Pyrrolidinylmethyl- and piperidinyl substituted decahydroisoquinolines as excitatory amino acid receptor antagonists

Also Published As

Publication number Publication date
MXPA06007007A (es) 2007-06-08
JP2007523829A (ja) 2007-08-23
EP1711462A1 (de) 2006-10-18
UA82753C2 (uk) 2008-05-12
CA2548391A1 (en) 2005-06-30
CN1942438A (zh) 2007-04-04
WO2005058816A1 (de) 2005-06-30
AU2003298077A1 (en) 2005-07-05
US20080176923A1 (en) 2008-07-24
AU2003298077A2 (en) 2005-07-05

Similar Documents

Publication Publication Date Title
ECSP034774A (es) Pirazolopirimmidinas como agentes terapeuticos
ECSP034773A (es) Pirazolopirimmidinas como agentes terapeuticos
SV2002000245A (es) Oxazolidinonas substituidas y su uso ref. lea 34122-sv
ECSP105253A (es) Derivados de 5-feniltiazol y uso como inhibidores de pi3 cinasa
CR8102A (es) Derivados de pirazolo- quinazolina, procedimiento para preparacion y su uso como inhibidores de quinasa
BRPI0418251B8 (pt) fosfonatos, monofosfonamidatos, bisfosfonamidatos, e, composição farmacêutica os compreendendo
TR200302242T2 (tr) Protein kinaz önleyicileri olarak pirolopirimidinler
SE0101387D0 (sv) Novel compounds
BRPI0410477A (pt) composto ou um sal farmaceuticamente aceitável do mesmo, método para a profilaxia ou tratamento de uma condição quiral em um mamìfero, formulação farmacêutica, combinação, uso de um composto, e, processo para preparar um composto
BRPI0015254C1 (pt) compostos derivados de carbamoiloxialquil-azólio, seu uso, bem como composição farmacêutica compreendendo os mesmos.
BRPI0508540A (pt) composto, composição farmacêutica, e, uso de um composto
BR0307267A (pt) Compostos heterocìclicos, ativos como inibidores de beta-lacta-mases
BRPI0413555A (pt) composto ou sal do mesmo, composição farmacêutica, uso de um composto ou sal, e, método para o tratamento de uma doença, para a fabricação de um composto e para a preparação de composto
BRPI0108395B8 (pt) derivados de pirrolopirimidinona, processos de preparação e uso
BR0309343A (pt) Composto, composição farmacêutica, uso de um composto, e, método de tratamento ou profilaxia de doenças ou condições humanas
BR0210122A (pt) Composto ou um sal farmaceuticamente aceitável do mesmo, método para o tratamento ou prevenção de uma doença, uso do composto ou de seu sal, e, método para preparar o mesmo
ECSP088246A (es) Nuevos derivados de benzotiazolona
DOP2002000422A (es) Agentes antibacterianos.
BR0309342A (pt) Composto, composição farmacêutica, uso de um composto, e, método de tratamento ou profilaxia de doenças ou condições humanas
ECSP055701A (es) Nuevos derivados de pirimidinamida y el uso de los mismos
BR0211995A (pt) Preparados de combinação de derivados de propanolamina substituìdos por arila com outras substâncias ativas e sua aplicação
BRPI0514032A (pt) composto, sais farmaceuticamente aceitáveis do mesmo, diastereÈmeros, enanciÈmeros ou misturas do mesmo, uso de um composto, composição farmacêutica, método para a terapia de depressão em um animal de sangue quente, e, processo para preparar um composto
SE0403171D0 (sv) New compounds
BRPI0414780B8 (pt) composto, uso do mesmo, composição farmacêutica, e, método para preparar um composto
SE0302546D0 (sv) New compounds

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2073 DE 28/09/2010.